Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Bone Marrow Transplant
    March 2024
  1. GIRARD L, Koh YJ, Koh LP, Chee YL, et al
    Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2024 Mar 5. doi: 10.1038/s41409-024-02254.
    >> Share

    February 2024
  2. NAKAYA Y, Nakamae H, Nishikubo M, Kondo E, et al
    Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma.
    Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02229.
    >> Share

  3. HIROSE A, Koh H, Nakamae M, Nakashima Y, et al
    A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02231.
    >> Share

  4. MOSER O, Ngoya M, Galimard JE, Dalissier A, et al
    Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study.
    Bone Marrow Transplant. 2024 Feb 8. doi: 10.1038/s41409-024-02226.
    >> Share

  5. AHMADI P, Ghandili S, Jakobs F, Konnopka C, et al
    Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.
    Bone Marrow Transplant. 2024 Feb 6. doi: 10.1038/s41409-024-02228.
    >> Share

    January 2024
  6. DE PHILIPPIS C, Zucchinetti C, Mannina D, Krampera M, et al
    Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2024 Jan 25. doi: 10.1038/s41409-024-02205.
    >> Share

  7. CHEN W, Shi J, Luo Y, Yu J, et al
    Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma.
    Bone Marrow Transplant. 2024 Jan 23. doi: 10.1038/s41409-023-02191.
    >> Share

  8. NABERGOJ M, Eikema DJ, Koster L, Platzbecker U, et al
    Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02193.
    >> Share

  9. OLUWOLE OO, Forcade E, Munoz J, de Guibert S, et al
    Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
    Bone Marrow Transplant. 2024 Jan 4. doi: 10.1038/s41409-023-02169.
    >> Share

  10. CABRERO M, Lopez-Corral L, Jarque I, de la Cruz-Vicente F, et al
    Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
    Bone Marrow Transplant. 2024 Jan 2. doi: 10.1038/s41409-023-02171.
    >> Share

    December 2023
  11. ZHANG X, Pang Y, Wei C, Liang D, et al
    Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.
    Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182.
    >> Share

  12. EL WARRAK S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, et al
    Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy.
    Bone Marrow Transplant. 2023 Dec 16. doi: 10.1038/s41409-023-02176.
    >> Share

  13. JINDAL N, C M, Mathew LJ, Kumbhalwar K, et al
    Fertility outcomes in patients desiring conception following autologous stem cell transplantation for hodgkin lymphoma using LACE conditioning.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02179.
    >> Share

  14. KATO K, Sugio T, Ikeda T, Yoshitsugu K, et al
    Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02156.
    >> Share

    November 2023
  15. IQBAL M, Jagadeesh D, Chavez J, Khurana A, et al
    Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
    Bone Marrow Transplant. 2023 Nov 16. doi: 10.1038/s41409-023-02148.
    >> Share

  16. PENA M, Montane C, Paviglianiti A, Hurtado L, et al
    Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas.
    Bone Marrow Transplant. 2023;58:1282-1285.
    >> Share

    October 2023
  17. GOYAL A, O'Leary D, Foss F
    Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2023 Oct 18. doi: 10.1038/s41409-023-02122.
    >> Share

  18. KORESAWA-SHIMIZU R, Suzuki R, Uehara Y, Hiramoto N, et al
    Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry.
    Bone Marrow Transplant. 2023 Oct 7. doi: 10.1038/s41409-023-02118.
    >> Share

    September 2023
  19. ALEIXO GFP, Wei W, Chen PH, Gandhi NS, et al
    The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2023 Sep 12. doi: 10.1038/s41409-023-02104.
    >> Share

  20. BAUR K, Buser A, Jeker LT, Khanna N, et al
    CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas.
    Bone Marrow Transplant. 2023;58:1048-1050.
    >> Share

    August 2023
  21. WANG J, Alkrekshi A, Dasari S, Lin HC, et al
    CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study.
    Bone Marrow Transplant. 2023 Aug 21. doi: 10.1038/s41409-023-02086.
    >> Share

  22. BACHANOVA V, Nachman PH
    Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders.
    Bone Marrow Transplant. 2023 Aug 19. doi: 10.1038/s41409-023-02084.
    >> Share

  23. ARSHAD S, Fang X, Ahn KW, Kaur M, et al
    Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.
    Bone Marrow Transplant. 2023 Aug 10. doi: 10.1038/s41409-023-02071.
    >> Share

  24. STYCZYNSKI J, Tridello G, Koster L, Knelange N, et al
    Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT.
    Bone Marrow Transplant. 2023;58:881-892.
    >> Share

    July 2023
  25. DAMLAJ M, Tlayjeh M, Damlaj A, Alahmari B, et al
    Contemporary outcomes of high risk relapsed refractory classical hodgkin lymphoma patients-role of maintenance therapy in the real world.
    Bone Marrow Transplant. 2023 Jul 18. doi: 10.1038/s41409-023-02036.
    >> Share

    June 2023
  26. OTHMAN T, Lowsky R, Richman C, Hoeg R, et al
    Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2023 Jun 30. doi: 10.1038/s41409-023-02025.
    >> Share

  27. MUSSETTI A, Bento L, Bastos-Oreiro M, Rius-Sansalvador B, et al
    Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
    Bone Marrow Transplant. 2023;58:673-679.
    >> Share

    May 2023
  28. AL-JUHAISHI T, Wang Y, Milton DR, Xu-Monette ZY, et al
    Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.
    Bone Marrow Transplant. 2023 May 18. doi: 10.1038/s41409-023-02006.
    >> Share

  29. INOUE Y, Morishima S, Kato K, Ito A, et al
    Impact of HLA-mismatched unrelated transplantation in patients with adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2023 May 12. doi: 10.1038/s41409-023-02002.
    >> Share

    April 2023
  30. PORTUGUESE AJ, Gauthier J, Tykodi SS, Hall ET, et al
    CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review.
    Bone Marrow Transplant. 2023;58:353-359.
    >> Share

    March 2023
  31. FUJI S, Inoue Y, Makiyama J, Nakano N, et al
    The clinical benefit of acute GVHD depends on the age at transplantation in patients with adult T-cell leukemia-lymphoma on behalf of the ATL Working Group of the Japan Society for Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2023 Mar 25. doi: 10.1038/s41409-023-01969.
    >> Share

    February 2023
  32. MIAN A, Wei W, Hamilton BK, Winter AM, et al
    Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel.
    Bone Marrow Transplant. 2023 Feb 11. doi: 10.1038/s41409-023-01934.
    >> Share

    January 2023
  33. TOKUNAGA M, Nakano N, Fuji S, Wake A, et al
    Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study.
    Bone Marrow Transplant. 2023 Jan 21. doi: 10.1038/s41409-023-01919.
    >> Share

    December 2022
  34. YANG F, Shi H, Xu T, Liu R, et al
    Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma.
    Bone Marrow Transplant. 2022 Dec 22. doi: 10.1038/s41409-022-01903.
    >> Share

  35. ALSULIMAN T, Stocker N, Corre E, Dulery R, et al
    Autologous hematopoietic cell transplantation as a part of a sequential multi-phase therapeutic approach (R-COPADM/CYVE/ASCT) as first-line treatment of high-grade B-cell lymphoma: results of a retrospective study with long-term follow-up.
    Bone Marrow Transplant. 2022 Dec 22. doi: 10.1038/s41409-022-01902.
    >> Share

  36. LIU W, Ji J, Zou D, Cao Y, et al
    Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China.
    Bone Marrow Transplant. 2022 Dec 17. doi: 10.1038/s41409-022-01899.
    >> Share

  37. YING Z, Xie Y, Zheng W, Liu W, et al
    Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial.
    Bone Marrow Transplant. 2022 Dec 7. doi: 10.1038/s41409-022-01888.
    >> Share

    November 2022
  38. DREGER P, Holtick U, Subklewe M, von Tresckow B, et al
    Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience.
    Bone Marrow Transplant. 2022 Nov 22. doi: 10.1038/s41409-022-01867.
    >> Share

    September 2022
  39. TANG B, Cai Z, Wang Z, Lin D, et al
    Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2022 Sep 2. pii: 10.1038/s41409-022-01797.
    >> Share

    August 2022
  40. ELLIOTT J, Ahlawat S, Prince HM, Kennedy G, et al
    Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides.
    Bone Marrow Transplant. 2022 Aug 26. pii: 10.1038/s41409-022-01787.
    >> Share

  41. JACOBSEN ED, Kim HT, Jeter E, Jacobson C, et al
    Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma.
    Bone Marrow Transplant. 2022 Aug 22. pii: 10.1038/s41409-022-01784.
    >> Share

  42. HANNA P, Strohbehn I, Moreno D, Harden D, et al
    Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma.
    Bone Marrow Transplant. 2022 Aug 3. pii: 10.1038/s41409-022-01767.
    >> Share

    July 2022
  43. MA J, Sun S, Hu Y, Wu M, et al
    Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL.
    Bone Marrow Transplant. 2022 Jul 25. pii: 10.1038/s41409-022-01766.
    >> Share

    June 2022
  44. MEISSNER J, Schmitt M, Andrulis M, Schweizer L, et al
    Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2022 Jun 9. pii: 10.1038/s41409-022-01734.
    >> Share

  45. YANG JC, Scordo M, Chau KW, Sauter CS, et al
    Highly favorable outcomes with salvage radiation therapy and autologous hematopoietic cell transplantation in relapsed and refractory DLBCL patients with minimal to no response to salvage chemotherapy.
    Bone Marrow Transplant. 2022;57:1038-1041.
    >> Share

    May 2022
  46. FERNANDEZ-SOJO J, Cid J, Azqueta C, Valdivia E, et al
    Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation.
    Bone Marrow Transplant. 2022 May 25. pii: 10.1038/s41409-022-01722.
    >> Share

  47. ANGELOV D, Dillon J, Mellerick L, Pender E, et al
    Allogeneic transplantation in Cutaneous T-cell Lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease.
    Bone Marrow Transplant. 2022 May 20. pii: 10.1038/s41409-022-01713.
    >> Share

  48. FRIETSCH JJ, Miethke J, Linke P, Crodel CC, et al
    Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2022 May 10. pii: 10.1038/s41409-022-01701.
    >> Share

    April 2022
  49. SCHENONE L, Houillier C, Tanguy ML, Choquet S, et al
    Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
    Bone Marrow Transplant. 2022 Apr 14. pii: 10.1038/s41409-022-01648.
    >> Share

  50. LIU H, Liu W, Li R, Jiao Y, et al
    A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma.
    Bone Marrow Transplant. 2022 Apr 7. pii: 10.1038/s41409-022-01655.
    >> Share

  51. HEINI AD, Bacher U, Kronig MN, Wiedemann G, et al
    Chimeric antigen receptor T-cell therapy for relapsed mantle cell lymphoma: real-world experience from a single tertiary care center.
    Bone Marrow Transplant. 2022 Apr 5. pii: 10.1038/s41409-022-01658.
    >> Share

    March 2022
  52. GALLI E, Sora F, Hohaus S, Bellesi S, et al
    Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma.
    Bone Marrow Transplant. 2022 Mar 8. pii: 10.1038/s41409-022-01632.
    >> Share

  53. HERNANDEZ-BOLUDA JC, Pereira A, Zinger N, Gras L, et al
    Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.
    Bone Marrow Transplant. 2022;57:416-422.
    >> Share

    February 2022
  54. YOON SE, Jo H, Kang ES, Cho D, et al
    Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis.
    Bone Marrow Transplant. 2022 Feb 16. pii: 10.1038/s41409-022-01605.
    >> Share

  55. COSTES-TERTRAIS D, Hueso T, Gastinne T, Thieblemont C, et al
    Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
    Bone Marrow Transplant. 2022 Feb 11. pii: 10.1038/s41409-022-01596.
    >> Share

  56. HUSBY S, Jorgensen GO, Favero F, Jespersen JS, et al
    Level of unique T cell clonotypes is associated with clonal hematopoiesis and survival in patients with lymphoma undergoing ASCT.
    Bone Marrow Transplant. 2022 Feb 5. pii: 10.1038/s41409-022-01580.
    >> Share

  57. FRIEND BD, Muhsen IN, Patel S, Hill LC, et al
    Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.
    Bone Marrow Transplant. 2022 Feb 1. pii: 10.1038/s41409-022-01599.
    >> Share

  58. WALLADBEGI J, Henriksson R, Tavelin B, Svanberg A, et al
    Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial.
    Bone Marrow Transplant. 2022;57:191-197.
    >> Share

    January 2022
  59. LIEVIN R, Di Blasi R, Morin F, Galli E, et al
    Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma.
    Bone Marrow Transplant. 2022 Jan 30. pii: 10.1038/s41409-021-01526.
    >> Share

    November 2021
  60. LEAL CTS, Costa LJM, Pereira J, Duarte FB, et al
    Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients.
    Bone Marrow Transplant. 2021 Nov 29. pii: 10.1038/s41409-021-01531.
    >> Share

    October 2021
  61. DWORKIN ML, Jiang AL, Von Eyben R, Spinner MA, et al
    Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant.
    Bone Marrow Transplant. 2021 Oct 20. pii: 10.1038/s41409-021-01495.
    >> Share

  62. SALVINI M, Maggi F, Damonte C, Mortara L, et al
    Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation.
    Bone Marrow Transplant. 2021 Oct 11. pii: 10.1038/s41409-021-01487.
    >> Share

  63. SELLNER L, Schetelig J, Koster L, Choi G, et al
    Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey.
    Bone Marrow Transplant. 2021 Oct 7. pii: 10.1038/s41409-021-01490.
    >> Share

  64. MILLARD T, Sammour F, Anthias C, Easdale S, et al
    Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?
    Bone Marrow Transplant. 2021 Oct 5. pii: 10.1038/s41409-021-01484.
    >> Share

    August 2021
  65. INOUE Y, Nakano N, Fuji S, Eto T, et al
    Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2021 Aug 31. pii: 10.1038/s41409-021-01445.
    >> Share

  66. MUNSHI PN, Hamadani M, Kumar A, Dreger P, et al
    ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma.
    Bone Marrow Transplant. 2021 Aug 20. pii: 10.1038/s41409-021-01288.
    >> Share

  67. TAMAI H, Tajika K, Nakayama K, Arai A, et al
    Treatment of relapsed aggressive adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation with mogamulizumab followed by lenalidomide.
    Bone Marrow Transplant. 2021 Aug 12. pii: 10.1038/s41409-021-01432.
    >> Share

  68. CORNILLON J, Daguenet E, Tournilhac O, Blaise D, et al
    Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire.
    Bone Marrow Transplant. 2021 Aug 6. pii: 10.1038/s41409-021-01426.
    >> Share

    July 2021
  69. LEW TE, Cliff ERS, Dickinson M, Tam CS, et al
    T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease.
    Bone Marrow Transplant. 2021 Jul 20. pii: 10.1038/s41409-021-01418.
    >> Share

  70. LOWENBERG B, Kersten MJ, Gale RP, van Oers M, et al
    Professor Anton Hagenbeek 1948-2021: Father of MRD and lymphoma expert.
    Bone Marrow Transplant. 2021 Jul 19. pii: 10.1038/s41409-021-01375.
    >> Share

  71. CORTELAZZO S, Mian M, Evangelista A, Devizzi L, et al
    Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term.
    Bone Marrow Transplant. 2021 Jul 7. pii: 10.1038/s41409-021-01391.
    >> Share

    June 2021
  72. GEVA M, Pryce A, Shouval R, Fein JA, et al
    High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2021 Jun 29. pii: 10.1038/s41409-021-01377.
    >> Share

  73. BONIFAZI F, Defrancesco I, Olivieri J, Barbato F, et al
    Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas.
    Bone Marrow Transplant. 2021 Jun 9. pii: 10.1038/s41409-021-01359.
    >> Share

    May 2021
  74. VIJENTHIRA A, Kuruvilla J, Prica A
    Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy.
    Bone Marrow Transplant. 2021 May 13. pii: 10.1038/s41409-021-01327.
    >> Share

  75. DERENZINI E, Tabanelli V, Sammassimo S, Mazzara S, et al
    Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma.
    Bone Marrow Transplant. 2021 May 7. pii: 10.1038/s41409-021-01320.
    >> Share

    April 2021
  76. TOYODA K, Yasunaga JI, Choi I, Suehiro Y, et al
    The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2021 Apr 29. pii: 10.1038/s41409-021-01311.
    >> Share

  77. EYRE TA, Caillard S, Finel H, Boumendil A, et al
    Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT.
    Bone Marrow Transplant. 2021 Apr 16. pii: 10.1038/s41409-021-01270.
    >> Share

  78. SHAPIRO LC, Mustafa J, Lombardo A, Khatun F, et al
    Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.
    Bone Marrow Transplant. 2021 Apr 12. pii: 10.1038/s41409-021-01280.
    >> Share

    March 2021
  79. PYTLIK R, Vackova B, Konirova E, Trnkova M, et al
    Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT.
    Bone Marrow Transplant. 2021;56:709-712.
    >> Share

    February 2021
  80. PRINCE HM, Abeyakoon C
    Allogeneic haematopoietic stem cell transplantation for advanced stage mycosis fungoides and Sezary syndrome: never-late, never-never?
    Bone Marrow Transplant. 2021 Feb 1. pii: 10.1038/s41409-020-01150.
    >> Share

    June 2020
  81. MERLI M, Luminari S, Farina L, Cocito F, et al
    Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi.
    Bone Marrow Transplant. 2020 Jun 15. pii: 10.1038/s41409-020-0967.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016